FDA Approves PHESGO Supplement for Genentech's Combination Therapy
The FDA has approved a supplemental application for PHESGO, a combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf.
Asset / Drug
Drug and asset intelligence for PHESGO with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.